PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Adoptive T-cell therapy with CD45RA-deplected donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients

    Yuste JR (1,2), Díaz de Cerio AL (3,4), Rifón J (4), Moreno C (3), Panizo M (1), Inogés S (3,4).

    (1) Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Department of Internal Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Immunology and Immuotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Hematology Service and Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.

    Antiviral Therapy 26 de MARÇO de 2019

  • Adiponectin-leptin Ratio is a Functional Biomarker of Adipose Tissue Inflammation

    Frühbeck G (1,2,3,4), Catalán V (5,6,7), Rodríguez A (8,9,10), Ramírez B (11,12,13), Becerril S (14,15,16), Salvador J (17,18), Colina I (19,20), Gómez-Ambrosi J (21,22,23)

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (4) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (5) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (7)  Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (8) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (9) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (10) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (11) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (12) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (13) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (14) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain
    (15) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (16) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (17) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (18) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (19) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (20) Department of Internal Medicine, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (21) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (22) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (23) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.

    Nutrients 22 de FEVEREIRO de 2019

  • A phenotypic map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites

    Martins-Filho SN (1,2), Alves VAF (1,3), Wakamatsu A (3), Maeda M (4), Craig AJ (4), Assato AK (3), Villacorta-Martin C (4), D'Avola D (5), Labgaa I (4,6), Carrilho FJ (7), Thung SN (8), Villanueva A (4,9).

    (1) Departamento de Patologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil.
    (2) Department of Pathology and Laboratory Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
    (3) Laboratorio de Patologia do Fígado LIM 14, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
    (4) Liver Cancer Research Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (5) Liver Unit, Clínica Universidad de Navarra, Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Pamplona, Spain.
    (6) Department of Visceral Surgery, Lausanne University Hospital CHUV, Switzerland.
    (7) Departamento de Gastroenterologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil.
    (8) Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (9) Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Histopathology 12 de JANEIRO de 2019

  • Assessment of indeterminate pulmonary nodules detected in lung cancer screening

    Collantes M (1,2), Martínez-Vélez N (3), Zalacain M (3,2), Marrodán L (3,2), Ecay M (4), García-Velloso MJ (1,2), Alonso MM (3,2), Patiño-García A (3,2), Peñuelas I (5,6,7).

    (1) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (2) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (3) Departamento de Pediatría, Clínica Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (4) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (5) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (6) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (7) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

    BMC Cancer 29 de NOVEMBRO de 2018

  • Adjuvants in allergen-specific immunotherapy: modulating and enhancing the immune response

    Zubeldia JM (1), Ferrer M (2), Dávila I (3), Justicia JL (4).

    (1) Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.
    (2) Department of Allergy, Clínica Universidad de Navarra, Pamplona, Spain. Department of Medical Education, School of Medicine, Navarra University, Pamplona, Spain.
    (3) Allergy Service, University Hospital of Salamanca, Salamanca, Spain. Department of Biomedical and Diagnostic Sciences, Faculty of Medicine of Salamanca, Salamanca, Spain. Institute for Biomedical Research, IBSAL, Salamanca, Spain.
    (4) Medical Department. Allergy Therapeutics Ibérica.

    Journal of Investigational Allergology & Clinical Immunology 12 de NOVEMBRO de 2018

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra